EUVIMEDOpdag EUVIMED
Crossref

Refractory patients with favorable/intermediate‐risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation

Yigeng Cao, Xinhui Zheng iD, Haixiao Zhang, Mingyang Wang, Wenwen Guo, Xin Chen, Weihua Zhai, Jialin Wei, Donglin Yang, Yong Huang, Aiming Pang, Sizhou Feng and 2 more

Hematological Oncology · 2024-01 · 42 (1)

DOI: 10.1002/hon.3232 ↗

At a glance

Journal article in Hematological Oncology, published online on 2023-10-04. Written by Yigeng Cao and 13 co-authors. Institution: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Major MEDLINE topics: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Cited 4 times so far (Crossref); 13 references. Funded by: Natural Science Foundation of Tianjin Municipality, Key Project of Tianjin Natural Science Foundation, National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Recurrence following allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the major cause of treatment failure in patients with myeloid malignancy. Azacytidine (AZA) maintenance is a promising therapy to prevent relapse and improve survival. We conducted a prospective, one‐arm study involving 78 patients with myeloid malignancy at a high risk of recurrence who were enrolled between September 2019 and April 2022. Furthermore, 102 matched historical controls were selected using propensity score matching. With a median follow‐up time of 19.6 (3.5–91.7) months, AZA maintenance therapy significantly improved relapse‐free survival (RFS; log‐rank test, p = 0.01). The AZA and control groups had a 1‐year RFS of 87.7% (95% confidence interval [CI], 0.80–0.96) and 72.2% (95% CI, 0.64–0.82), respectively, with a hazard ratio (HR) of 0.21 (95% CI, 0.09–0. 47; p < 0.01). There were no grade 4 adverse effects or deaths related to AZA. Refractory patients with favorable/intermediate‐risk acute myeloid leukemia (AML) benefited more from AZA maintenance therapy than those with adverse‐risk AML according to the European Leukemia Net guidelines (RFS in favorable/intermediate‐risk AML, HR = 0.29, 95% CI, 0.11–0.79; RFS in adverse‐risk AML, HR = 0.57, 95% CI, 0.21–1.6; p for interaction = 0.03). Our findings suggest that AZA maintenance therapy following allo‐HSCT was safe and could reduce the incidence of relapse, particularly for refractory patients with favorable/intermediate‐risk AML.

Subjects

MeSH terms (MEDLINE)

Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationHumansAzacitidineProspective StudiesTransplantation, HomologousChronic DiseaseRecurrenceRetrospective Studies

Author keywords

azacytidinehematopoietic stem cell transplantation

Substances

Azacitidine

Authors and institutions

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…

ORCID profiles: Xinhui Zheng, Erlie Jiang

Funding

  • Natural Science Foundation of Tianjin Municipality
  • Key Project of Tianjin Natural Science Foundation
  • National Natural Science Foundation of China
  • Haihe Laboratory of Cell Ecosystem Innovation Fund
  • CAMS Innovation Fund for Medical Sciences

Cite

APA

Cao, Y., Zheng, X., Zhang, H., Wang, M., Guo, W., Chen, X., Zhai, W., Wei, J., Yang, D., Huang, Y., Pang, A., Feng, S., Jiang, E., & Han, M. (2024). Refractory patients with favorable/intermediate‐risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation. Hematological Oncology, 42(1). https://doi.org/10.1002/hon.3232

Vancouver

Cao Y, Zheng X, Zhang H, Wang M, Guo W, Chen X, et al. Refractory patients with favorable/intermediate‐risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation. Hematological Oncology. 2024;42(1). doi:10.1002/hon.3232

BibTeX
@article{Cao2024,
  author = {Cao, Yigeng and Zheng, Xinhui and Zhang, Haixiao and Wang, Mingyang and Guo, Wenwen and Chen, Xin and Zhai, Weihua and Wei, Jialin and Yang, Donglin and Huang, Yong and Pang, Aiming and Feng, Sizhou and Jiang, Erlie and Han, Mingzhe},
  title = {Refractory patients with favorable/intermediate‐risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation},
  journal = {Hematological Oncology},
  year = {2024},
  volume = {42},
  number = {1},
  doi = {10.1002/hon.3232}
}
Start for free →